Specifically, for example, the prophylactic use of G-CSF (filgrastim, lenograstim, pegfilgrastim) during CHRT for patients with small cell lung cancer promoted a significant reduction in the incidence of neutropenia without any increase in hematologic or radiotherapy-related toxicity [18]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.